Company profile for Savara

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, AeroVanc and amikacin/fosfomycin. Molgradex is an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, and in Phase 2a development for nontuberculous mycobacteria, or NTM, in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lu...
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, AeroVanc and amikacin/fosfomycin. Molgradex is an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, and in Phase 2a development for nontuberculous mycobacteria, or NTM, in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection. AeroVanc, is a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Sstaphylococcus aureus, or MRSA, lung infection in CF.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Savara Inc. 6836 Bee Cave Road, Building 3, Suite 200 Austin, TX, 78746
Telephone
Telephone
+1 (512) 614-1848
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251221214643/en/Savara-Resubmits-the-Biologics-License-Application-BLA-to-the-U.S.-Food-and-Drug-Administration-FDA-for-MOLBREEVI-for-the-Potential-Treatment-of-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP

BUSINESSWIRE
22 Dec 2025

https://www.businesswire.com/news/home/20251217079438/en/Savara-Announces-Participation-in-the-44th-Annual-J.P.-Morgan-Healthcare-Conference

BUSINESSWIRE
17 Dec 2025

https://www.businesswire.com/news/home/20251211393845/en/Savara-Announces-European-Patent-Office-EPO-Intends-to-Grant-a-Patent-for-the-Liquid-Formulation-of-MOLBREEVI

BUSINESSWIRE
11 Dec 2025

https://www.businesswire.com/news/home/20251120941519/en/Savara-Announces-Participation-in-Upcoming-Investor-Healthcare-Conferences

BUSINESSWIRE
20 Nov 2025

https://www.businesswire.com/news/home/20251112721405/en/Savara-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update

BUSINESSWIRE
12 Nov 2025

https://www.businesswire.com/news/home/20251103285242/en/Savara-Announces-Participation-in-Upcoming-Investor-Healthcare-Conferences

BUSINESSWIRE
03 Nov 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty